24/7 Market News Snapshot 17 December, 2024 – Marker Therapeutics, Inc. Common Stock (NASDAQ:MRKR)

December 17, 2024

DENVER, Colo., 17 December, 2024 (247marketnews.com) – (Nasdaq:MRKR) are discussed in this article.
Marker Therapeutics, Inc. (Nasdaq:MRKR) has recently experienced a notable surge in its stock performance, opening at $4.20 and reaching an impressive high of $5.455, marking a significant increase of 32.08% from the previous close of $4.13. This upward trajectory reflects strong investor confidence and heightened interest in the company’s future prospects, as evidenced by a robust trading volume of 509.04K shares. Such a remarkable rally suggests a turning point for Marker Therapeutics, making it a key stock for investors to monitor closely.

In tandem with its stock performance, Marker Therapeutics has been awarded a $9.5 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT), designated to further the clinical research of its flagship asset, MT-601, specifically for patients suffering from metastatic pancreatic cancer. This funding will bolster the Phase 1 PANACEA study, which aims to evaluate the safety and tolerability of MT-601, a novel multi-tumor associated antigen (multiTAA)-specific T cell product designed to target various tumor-specific antigens prevalent in multiple cancer types.

Dr. Juan Vera, President and CEO of Marker Therapeutics, emphasized the significance of the CPRIT grant, stating that it highlights the innovative potential of MT-601 and its importance in tackling the formidable challenges associated with pancreatic cancer treatment. This newly secured funding adds to the company’s previous achievements, which include securing over $30 million in non-dilutive funding from various government sources, allowing for the prioritization of clinical advancements without compromising ongoing studies in other cancer types.

The commencement of the Phase 1 study is expected in 2025, underpinned by encouraging preliminary data that demonstrate favorable safety and durable cancer control results from earlier trials involving similar T cell therapies for pancreatic cancer. With solid financial support and a commitment to clinical innovation, Marker Therapeutics is well-positioned to further its mission of developing effective immunotherapies for multiple cancers.

Related news for (MRKR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.